Listen to downloadable audio from a live Webinar in which CCO’s expert faculty reviewed the most clinically relevant new HIV data presented at CROI 2019 and answered questions from participants.
Here’s my summary of interesting new data to look forward to from CROI 2019.
Among the most noteworthy data presented at CROI 2019 were results from the phase III ATLAS and FLAIR studies of long-acting injectable cabotegravir plus rilpivirine. Here’s my take on how this regimen, if approved, could benefit people living with HIV.
In this downloadable slideset, expert faculty members summarize key studies from this important annual conference.
This expert-led Conference Coverage provides a comprehensive review of key data on the prevention and management of HIV infection from the 2019 Conference on Retroviruses and Opportunistic Infections.